secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2023-01-03T23:59:59+00:00
Accession:  0001193125-23-000830
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics reports positive Phase 2b ORIGIN topline: primary endpoint met in IgA nephropathy
--------------------------------------------------------------------------------

- UPCR reduced 31% with pooled 75/150 mg dose (p=0.037 vs placebo) and 33% with 150 mg (p=0.047) at week 24.
- eGFR stabilized in atacicept arm through week 24; Gd-IgA1 reduced robustly from baseline.
- Safety well-tolerated: 1% discontinuation due to AEs, serious TEAEs 2% atacicept vs 9% placebo.
- Company plans to advance atacicept into pivotal Phase 3 development in H1 2023 subject to FDA discussions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312523000830/0001193125-23-000830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312523000830/d445567d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-000830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer